BPC-157
This 15-amino-acid synthetic peptide has shown tissue-repair signals mainly in laboratory and animal studies. Adequately powered human trials are missing.
Learn what you want to know about hormone therapy by scheduling a free consultation.
Contact Us Today609 N Hepburn Ave Ste 106, Jupiter, FL 33458
Monday - Friday: 9:00 am - 5:00 pm | Saturday-Sunday: Closed
© NovaGenix. All Rights Reserved. | Privacy Policy | ADA Compliance | Medical Disclaimer | Maintained by Digital Resource
THE PATIENT AND ANY OTHER PERSON RESPONSIBLE FOR PAYMENT HAS A RIGHT TO REFUSE TO PAY, CANCEL PAYMENT, OR BE REIMBURSED FOR PAYMENT FOR ANY OTHER SERVICE, EXAMINATION, OR TREATMENT THAT IS PERFORMED AS A RESULT OF AND WITHIN 72 HOURS OF RESPONDING TO THE ADVERTISEMENT FOR THE FREE, DISCOUNTED FEE, OR REDUCED FEE SERVICE, EXAMINATION, OR TREATMENT.
The “Wolverine stack” is the informal name for a combination of two synthetic peptides, BPC-157 and TB-500, used together in the hope of speeding soft-tissue recovery. The name comes from the comic-book character, not from any medical body, and it is not a recognized clinical protocol. As of September 2026, neither compound is FDA-approved for any indication.
Timothy Mackey, D.O., Medical Director
Florida License OS9185 · Medical review updated September 2026

Timothy Mackey, D.O.
Physician-led evaluation and monitoring
The Wolverine Stack combines BPC-157 and TB-500, usually by injection, based on the idea that their proposed pathways may complement one another. That rationale has not been demonstrated in human clinical trials. There is no recognized standard dose, cycle length, or clinical protocol.
This 15-amino-acid synthetic peptide has shown tissue-repair signals mainly in laboratory and animal studies. Adequately powered human trials are missing.
This synthetic thymosin beta-4 fragment is promoted for systemic recovery, but evidence from studies of the full protein does not automatically transfer to TB-500 products.
Neither compound is FDA-approved. Human effectiveness, dosing, product consistency, and long-term safety remain uncertain.
They are frequently discussed together online, sometimes as the “Wolverine Stack,” but they are different experimental peptides with different proposed pathways and evidence bases.
| Question | TB-500 | BPC-157 |
|---|---|---|
| What is it? | Synthetic fragment modeled on thymosin beta-4 | Synthetic peptide derived from a gastric protein sequence |
| Human injury evidence | Very limited | Limited; most evidence remains preclinical |
| FDA-approved? | No | No |
| Competitive sport | Anti-doping restrictions may apply | Listed by WADA as a non-approved substance |
Do not buy injectable peptides from social media, overseas sellers, or websites marked “research use only.” Call 911 for an emergency and contact a clinician promptly for concerning symptoms.
Review symptoms, imaging, training load, medications, health history, and prior rehabilitation.
Discuss established treatments, supportive care, and investigational options without overstating certainty.
When treatment is appropriate and lawfully available, define monitoring, stop criteria, and next steps.
No. Neither BPC-157 nor TB-500 is FDA-approved for any indication.
That claim has not been established in robust human trials. Preclinical findings are not proof of clinical benefit.
NovaGenix does not sell these peptides or direct patients to online research-chemical sellers. A physician can assess the underlying concern and discuss lawful options.
Athletes should assume anti-doping rules may apply and verify the current WADA list and their sport’s policies.
If an injury is not resolving or recovery has slowed, start with a diagnosis and a physician-led review—not an online protocol.